Department of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA.
Department of Bioengineering, University of California, Los Angeles, Los Angeles, California, USA.
Sci Rep. 2016 Aug 23;6:31915. doi: 10.1038/srep31915.
There is growing interest in developing drugs that specifically target glioblastoma tumor-initiating cells (TICs). Current cell culture methods, however, cannot cost-effectively produce the large numbers of glioblastoma TICs required for drug discovery and development. In this paper we report a new method that encapsulates patient-derived primary glioblastoma TICs and grows them in 3 dimension thermoreversible hydrogels. Our method allows long-term culture (50 days, 10 passages tested, accumulative ~>10(10)-fold expansion) with both high growth rate (20-fold expansion/7 days) and high volumetric yield (~2.0 × 10(7) cells/ml) without the loss of stemness. The scalable method can be used to produce sufficient, affordable glioblastoma TICs for drug discovery.
人们越来越感兴趣的是开发专门针对神经胶质瘤肿瘤起始细胞(TICs)的药物。然而,目前的细胞培养方法无法经济有效地产生大量用于药物发现和开发的神经胶质瘤 TIC。在本文中,我们报告了一种新的方法,该方法将患者来源的原发性神经胶质瘤 TIC 包封并在 3 维热可逆水凝胶中生长。我们的方法允许长期培养(50 天,测试了 10 个传代,累积>10(10)-倍扩增),具有高增长率(20 倍扩增/7 天)和高体积产率(2.0×10(7)个细胞/ml),而不会丧失干性。这种可扩展的方法可用于产生足够的、负担得起的神经胶质瘤 TIC,用于药物发现。